Breaking News

Tweet TWEET

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice
President of Marketing

Proven Global Renal Marketing Expert Joins Commercial Team

NEW YORK, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX), a biopharmaceutical company focused on the acquisition,
development and commercialization of pharmaceutical products for the treatment
of renal disease, today announced the appointment of Abraham Ceesay as Vice
President of Marketing and Operations. In this role, Mr. Ceesay will develop
and lead all aspects of the Zerenex^TM launch strategy and execution,
including brand planning, forecasting and analysis, marketing operations and
patient access programs. The Company's new drug application for Zerenex
(ferric citrate coordination complex) is currently under review by the FDA
with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7,
2014.

Greg Madison, the Company's Executive Vice President, Chief Operating Officer,
commented, "Mr. Ceesay brings an exceptional track record for successful
marketing and product launches of innovative products, including significant
renal experience. While at Genzyme, I saw first hand Abe's competencies in the
development of launch initiatives, brand creation strategies and marketing
efforts to maximize the commercial potential for renal drugs. We look forward
to leveraging Abe's capabilities for the potential launch and marketing of
Zerenex."

Mr. Ceesay brings to Keryx extensive experience in the launch and growth of
innovative therapeutic products and a strong track record in the leadership of
global commercial teams. Prior to joining Keryx, Mr. Ceesay served as Vice
President, Marketing at Ironwood Pharmaceuticals (Nasdaq:IRWD), where he held
responsibility for the management of the U.S. linaclotide P&L, leadership of
the Linzess^® brand team and co-promotion collaboration with Forest
Laboratories. In his role, Mr. Ceesay developed and led all facets of the
Linzess^® launch strategy and also led the cross functional U.S. Operating
Team responsible for the commercial and development decisions to support the
commercialization of Linzess^®. Previous to his career with Ironwood, Mr.
Ceesay spent eight years at Genzyme/Sanofi, initially as a field sales
specialist and ultimately as the Director, Renal Global Marketing, in which
capacity he held marketing responsibility for the company's renal franchise
(Renagel^®, Renvela^®, Hectorol^®). Over the course of his career at Genzyme,
Mr. Ceesay developed and implemented brand strategies for the global renal
franchise, including all marketing facets of the Renvela^® launch strategy.
Mr. Ceesay holds a bachelors degree from Ithaca College, and a Masters of
Business Administration from Suffolk University's Sawyer School of Management.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of pharmaceutical products for the treatment of renal
disease. Keryx is developing Zerenex^TM (ferric citrate coordination complex),
an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase
3 clinical program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with chronic kidney disease on dialysis, conducted
pursuant to a Special Protocol Assessment ("SPA") agreement with the FDA.
Keryx's New Drug Application ("NDA"), submitted to the FDA in 2013, is
currently under review and has an assigned Prescription Drug User Fee Act
("PDUFA") goal date of June 7, 2014. Zerenex has also completed a Phase 2
study in the U.S. for the management of elevated serum phosphorus levels and
iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent
chronic kidney disease. In addition, Keryx's Japanese partner, Japan Tobacco,
Inc. and Torii Pharmaceutical Co., Ltd., received marketing approval of ferric
citrate in Japan for the treatment of hyperphosphatemia in patients with
chronic kidney disease on January 17, 2014. Keryx is headquartered in New York
City.

Cautionary Statement

Some of the statements included in this press release, particularly those
relating to the results of clinical trials, the clinical benefits to be
derived from Zerenex, regulatory submissions and approvals, the commercial
opportunity and competitive positioning, and any business prospects for
Zerenex, may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause our actual
results to differ materially are the following: acceptance of the NDA filing
represents only a preliminary evaluation of the application and is not
indicative of deficiencies that may be identified during the FDA's review; a
PDUFA goal date is subject to change and does not guarantee that the review of
the NDA will be completed on a timely basis; the risk that the FDA, and/or EMA
ultimately deny approval of the U.S. NDA, and/or MAA, respectively; the risk
that SPAs are not a guarantee that the FDA will ultimately approve a product
candidate following filing acceptance; whether the FDA and EMA will concur
with our interpretation of our Phase 3 study results, supportive data, or the
conduct of the studies; whether Riona^® will be successfully launched and
marketed by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical
Co., Ltd.; whether, Zerenex, if approved by the FDA and/or EMA, will be
successfully launched and marketed; and other risk factors identified from
time to time in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as
of the date of this press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not incorporated
by reference into this press release and is included for reference purposes
only.

CONTACT: KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com

Keryx Logo
 
Press spacebar to pause and continue. Press esc to stop.